EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services confirmed approval for its Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy (WiSE CRT) System under the New Technology Add-On Payment (NTAP) scheme for Medicare inpatients, according to a Tuesday filing with the Australian bourse.
The confirmation ensures a maximum reimbursement rate of up to $41,145, based on an average WiSE selling price of $63,300, in addition to Diagnosis Related Group payments for procedure and device costs, the filing said.
The NTAP reimbursement will remain in effect for three years, according to the filing.
Shares rose more than 7% in morning trade on Tuesday.